Joseph Lynskey was shoved into the path of an oncoming train and survived. On Monday, he thanked the firefighters who rescued him. By Katherine Rosman New York lawmakers may give Gov.

Evercore ISI analyst Cory Kasimov maintained a Buy rating on Neurocrine (NBIX – Research Report) on January 31 and set a price target of $190.00. The company’s shares closed last Friday at ...

Morgan Stanley raised the firm’s price target on Neurocrine (NBIX) to $185 from $170 and keeps an Overweight rating on the shares. The share price is up 32% from 12-month lows in early October ...

Neurocrine Biosciences stock is a buy due to robust sales growth, augmented by the FDA approval of CRENESSITY in December 2024. INGREZZA dominates current sales, but CRENESSITY, a new treatment ...

Neurocrine Biosciences stock opened at $150.10 on Tuesday. The stock has a market cap of $15.20 billion, a price-to-earnings ratio of 40.24 and a beta of 0.33. The company’s 50-day moving ...

At Home with Katherine Ryan is back for another season on U&W as the comedian navigates everything from teen social media addiction to how to trust your husband to fertility tests, all while ...

Neurocrine Biosciences, Inc. has a 52-week low of $110.95 and a 52-week high of $157.98. The firm has a market cap of $15.20 billion, a P/E ratio of 40.24 and a beta of 0.33. Analyst Upgrades and ...

The "targeted" shooting occurred on Monday night in Coconut Grove, and three alleged offenders were arrested in Katherine on Tuesday morning. Three people have been arrested after a man was shot ...

Shares in Neurocrine Bioscience took a tumble after the company reported mid-stage data for a key pipeline drug for schizophrenia that failed to impress investors. The 19% after-market selloff ...

Joseph Menn joined The Post in 2022 after two decades covering technology for Reuters, the Financial Times and the Los Angeles Times. His books include "Cult of the Dead Cow: How the Original ...